RRRaúl Rashid-López

Raúl Rashid-López

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Raúl Rashid-López has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multimodal neuroimaging and serum biomarkers of slowed information processing speed in mildly disabled individuals with multiple sclerosis

    by Álvaro J. Cruz-Gómez, Lucía Forero, Fátima Cano-Cano, Mónica García-Corrales, Elena Lozano-Soto, Florencia Sanmartino, Raúl Espinosa-Rosso, Raúl Rashid-López, Javier J. González-Rosa

    Background: Slowed information processing speed (IPS) is an early and prevalent cognitive feature of relapsing–remitting multiple sclerosis (RRMS), although its neurobiological mechanisms remain poorly understood. This study investigated the multimodal basis of IPS impairment in mildly disabled RRMS patients by integrating structural MRI, resting-state functional connectivity (FC), and serum biomarkers of neuroaxonal (sNfL) and astrocytic (sGFAP) injury.Methods: Forty-three individuals with RRMS and 29 healthy controls (HCs) underwent neuropsychological assessment, blood sampling, and MRI scanning. Gray matter (GM) voxel-based morphometry and resting-state independent component analysis (ICA) were performed. RRMS patients were stratified into high-IPS and low-IPS subgroups based on their performance in neuropsychological tests.Results: Compared with HCs, RRMS patients exhibited significant IPS impairment, bilateral thalamic GM atrophy, and elevated sNfL levels. Subgroup stratification revealed a clear dissociation: low-IPS patients showed pronounced bilateral thalamic atrophy, higher white matter lesion volume, and elevated sNfL and sGFAP levels relative to high-IPS patients. In contrast, high-IPS patients showed no evidence of GM atrophy or abnormal sNfL levels compared with HCs, but exhibited significantly increased FC within sensorimotor cortical regions. Stepwise multiple regression identified thalamic GM volume as the strongest independent predictor of IPS, with sGFAP levels and sensorimotor network FC providing significant incremental explanatory value.Conclusions: These findings reveal a clinico-biological dissociation in RRMS. While IPS impairment is driven by neuroaxonal injury and structural collapse, cognitive preservation is maintained through adaptive sensorimotor network reorganization. This functional compensation appears to mitigate cognitive decline until a critical structural damage threshold is reached.

  • Cortical–Subthalamic Interplay During Eyes-Open and Eyes-Closed Resting States in Parkinson’s Disease Patients

    by Florencia Sanmartino, Raúl Rashid-López, Fernando López-Sosa, Álvaro Javier Cruz-Gómez, Elena Lozano-Soto, Jesús Riqué-Dormido, Raúl Espinosa-Rosso, Javier Jesús González-Rosa

    Resting-state eye conditions modulate cortical oscillations, but their impact on subthalamic nucleus (STN) and cortico–STN dynamics in Parkinson’s disease (PD) remains poorly understood. Here, we characterized electrophysiological changes in the STN and cortical interactions during eyes-open (EO) and eyes-closed (EC) conditions in 12 PD patients undergoing deep brain stimulation surgery. Spontaneous local field potentials in the STN (STN-LFP) and surface electroencephalogram (EEG) activity were simultaneously obtained on postoperative days 2–3 in the OFF-medication state. Power spectral density (PSD), coherence (COH), and Granger causality measures between STN-LFPs and frontal–occipital cortical areas were analyzed. These metrics revealed significant EO–EC differences, particularly in the low-frequency (LF, 4–12[ ]Hz) range. Although LF power increased across all regions during EC relative to EO, only STN and frontal EEG showed statistically significant changes. EC elicited increased frontal–STN COH within both the LF and low-beta bands (13–21[ ]Hz), accompanied by enhanced occipital–STN coupling in the low-beta range. In contrast, the influence of the alpha-band frontal cortex on the STN was more pronounced during EO. These findings confirm that eye states may differentially modulate functional connectivity through widespread cortical and STN–cortical interactions and suggest that, in unmedicated PD, EC and EO dynamically modulate large-scale cortical–STN network activity.


  • Open Access

    Bilateral intermittent theta burst stimulation over the primary motor cortex improves motor and affective symptoms via thalamic network reintegration in mid-stage Parkinson's disease

    by Paloma Macías-García, Raúl Rashid-López, Álvaro J. Cruz-Gómez, Francisco L. Sánchez-Fernández, Esteban Sarrias-Arrabal, Fátima Cano-Cano, Elena Lozano-Soto, Florencia Sanmartino, Raúl Espinosa-Rosso, Javier J. González-Rosa

  • Open Access

    Plasticity-Induced Motor Recovery of Bilateral Intermittent Theta Burst Stimulation in Parkinson’s Disease: A Randomized, Double-Blind, Sham-Controlled, Crossover Trial

    by Raúl Rashid-López, Paloma Macías-García, Álvaro J. Cruz-Gómez, Fátima Cano-Cano, Francisco L. Sánchez-Fernández, Esteban Sarrias-Arrabal, Ángel Del Marco, Álvaro González-Moraleda, Elena Lozano-Soto, Florencia Sanmartino, et al.

    Introduction Cortico-subcortical dysfunction from dopaminergic depletion is a hallmark of Parkinson’s disease (PD). Modulating primary motor cortex (M1) excitability with intermittent theta burst stimulation (iTBS) may restore network integrity in PD by targeting neurobiological changes at excitatory, structural, and serological levels. This study aimed to demonstrate the clinical and neurobiological effects of bilateral M1 iTBS in patients with PD. Methods Seventeen patients with Hoehn-Yahr stage II–III PD in the on-medication state underwent daily bilateral M1 iTBS sessions for 5 consecutive days in a randomized, double-blind, placebo-controlled, crossover design. The primary clinical outcomes were the relative change from baseline at four follow-up points after the final iTBS session, measured by the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Parts II, III, and IV. Changes in corticospinal excitability, structural brain imaging, and serum biomarkers of neurodegeneration, astrocytic activation, and neuroplasticity were also assessed. Results Real iTBS induced a significant improvement in MDS-UPDRS Part III scores, yielding more than twice the therapeutic benefit observed with sham stimulation. Responders (> 20% improvement) showed a mean 9-point improvement. Similarly, real iTBS stimulation resulted in an increase in corticospinal excitability of the clinically most affected hemisphere. In responders, serum brain-derived neurotrophic factor levels increased along with an increase in left ventral diencephalon volume, which was the strongest predictor of clinical response. Conclusion Bilateral M1 iTBS may represent a valuable adjunctive therapeutic option for pharmacological treatment of motor symptoms in patients with PD by promoting structural brain changes and enhancing synaptic plasticity in intermediate disease stages. Clinical Trial Registration https://clinicaltrials.gov/: NCT06840145, retrospectively registered on September 9, 2023.


  • Open Access

    Subthalamic stimulation elicits different transient properties of cortical rhythms during open-eyes and closed-eyes resting states

    by Constantino Méndez-Bértolo, Florencia Sanmartino, Fernando López-Sosa, Álvaro J. Cruz-Gómez, Elena Lozano-Soto, Raúl Espinosa-Rosso, Raúl Rashid-López, Javier J. González-Rosa

  • Open Access

    Short-term effects of subthalamic deep brain stimulation on clinical symptoms and biomarkers of neurodegeneration in Parkinson's disease

    by Florencia Sanmartino, Raúl Rashid-López, Álvaro J. Cruz-Gómez, Elena Lozano-Soto, Fátima Cano-Cano, Fernando López-Sosa, Jesús Riqué, Raúl Espinosa-Rosso, Javier J. González-Rosa

  • Open Access

    Impaired proactive control in Parkinson's disease and right prefrontal networks: findings from cortical source analysis during subthalamic stimulation

    by Fernando López-Sosa, Florencia Sanmartino, Raúl Rashid-López, Álvaro J. Cruz-Gómez, Elena Lozano-Soto, Jesús Riqué, Raúl Espinosa-Rosso, Javier J. González-Rosa

  • Open Access

    Neuropsychiatric Symptoms in Clinically Defined Parkinson’s Disease: An Updated Review of Literature

    by Paloma Macías-García, Raúl Rashid-López, Álvaro J. Cruz-Gómez, Elena Lozano-Soto, Florencia Sanmartino, Raúl Espinosa-Rosso, Javier J. González-Rosa

    Background. Neuropsychiatric symptoms (NPS) are a common and potentially serious manifestation of Parkinsons disease (PD) but are frequently overlooked in favor of a focus on motor symptomatology. Here, we conducted a literature review of the prevalence and type of NPS experienced by PD patients with a clinically defined course of their illness. Methods. We identified reports of NPS in patients with PD and mean disease duration over 3 years. Three databasesPubMed, Scopus, and Dialnetwere searched for relevant literature published between 2010 and 2020. Predefined exclusion criteria were applied prior to a descriptive analysis of the literature base. Results. In all, 87 unique reports were identified and 30 met inclusion and exclusion criteria. These included 7142 patients with PD (male: 67.3; mean age: 66.2 years; mean disease duration: 6.7 years). The most frequent NPS were mood disorders (apathy, depression, and anxiety), psychosis, and impulse control disorders (ICD). Treatment with dopamine agonists was identified as an important risk factor for ICD. Co-occurrence of NPS and cognitive dysfunction was also evidenced in a number of studies. Patients with more significant cognitive deficits and higher levels of NPS appeared to be of older age with a longer disease duration and to have more severe motor symptoms. Conclusions. NPS, most commonly mood disorders (apathy, depression, and anxiety), psychosis, and ICDs are frequent manifestations of PD. The results of this review reflect the need to develop unified validated assessment protocols for NPS in PD, as well as to improve their management in clinical practice.